Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics Inc (NQ: TPST )

0.9055 +0.0119 (+1.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempest Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
The company is preparing for the Phase 3 study start in the first quarter of 2025 
From Tempest Therapeutics
Via GlobeNewswire
Tempest Extends Limited Duration Stockholder Rights Plan
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal study 
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
Expansion of leadership team to strengthen global clinical expertise 
From Tempest Therapeutics
Via GlobeNewswire
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin... 
Via Benzinga
Exposures Product Safety
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024
TPST stock results show that Tempest Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Via Benzinga
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients... 
Via Benzinga
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday. 
Via InvestorPlace
Why Is Avrobio (AVRO) Stock Moving Today?
Avrobio stock is in the news Thursday as the company prepares for a merger and reverse stock split of AVRO after markets close today. 
Via InvestorPlace
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Is Tempest Therapeutics (TPST) Stock Up 45% Today?
Tempest Therapeutics stock is up on Thursday with heavy trading of TPST shares ahead of a presentation taking place this morning. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.